Interventional News’ most popular stories from June included a letter from the joint editor-in-chief on the current state of interventional radiology (IR) practice and where it needs to be; an interview with a New Zealand interventional radiologist on Australasian interventional oncology (IO); and news of the launch of several devices, including for mechanical thrombectomy, and to treat peripheral arterial disease (PAD).
1) Teleflex announces US FDA clearance with MRI of Arrow EZ-IO Needle for use with MRI
Teleflex has announced that the Arrow EZ-IO Needle is the first and only intraosseous (IO) needle to receive 510(k) clearance from the US Food and Drug Administration (FDA) for magnetic resonance (MR) conditional labelling. The EZ-IO Needle has a patented diamond tip designed for fast, precise and steady insertion.
According to a company press release, RevCore is the first mechanical thrombectomy device designed to address venous in-stent thrombosis. The Triever16 Curve catheter is purpose-built to be versatile for both pulmonary embolism and peripheral thrombectomy.
3) Biotronik launches Oscar multifunctional peripheral catheter at LINC 2023
Biotronik shared the limited release of its Oscar (One Solution: Cross. Adjust. Restore) multifunctional peripheral catheter and start of promotional activities at this year’s Leipzig Interventional Course (LINC 2023; 6–9 June, Leipzig, Germany).
4) “Doing better” for IR in Australia and New Zealand, from specialty status to qualification
Nick Brown (The Wesley Hospital, Auchenflower, New Zealand) sat down with Interventional News at the European Conference on Interventional Oncology (ECIO; 16–19 April, Stockholm, Sweden) to discuss the current picture of IR and IO in Australasia.
5) Merit Medical announces series of dialysis catheter acquisitions
According to a company press release, Merit Medical Systems has completed the acquisition of a portfolio of dialysis catheter products and the BioSentry biopsy tract sealant system.
6) US FDA approves Endologix’s Detour System for complex PAD
Endologix has announced in a press release that the US Food and Drug Administration (FDA) has granted approval for the Detour System to treat patients with complex PAD.
7) Editor’s letter: Beyond needles and images
Interventional News’ joint editor-in-chief Andreas Adam traces the evolution of interventional radiology and shares what he believes the modern interventional radiologist needs to have in their armoury and have access to, in order to provide the best care to patients.
8) Surmodics receives FDA approval for the SurVeil drug-coated balloon
A company press release notes that the SurVeil DCB may now be marketed and sold in the USA to physicians for percutaneous transluminal angioplasty, after appropriate vessel preparation, of de novo or restenotic lesions (≤180mm in length) in femoral and popliteal arteries having reference vessel diameters of 4mm to 7mm.
9) Argon Medical launches SuperCore Advantage in the USA
Argon Medical has announced the launch of the SuperCore Advantage semi-automatic biopsy instrument as the newest addition to its soft tissue biopsy product portfolio in the USA.
The ‘Connect the world: Japan’ session at this year’s Leipzig Interventional Course (LINC 2023, 6–9 June, Leipzig, Germany)—in collaboration with the Japanese Endovascular Treatment Conference (JET)—sparked discussion surrounding the latest data in femoropopliteal interventions.
